Healthcare
Olympus Reports First Quarter Fiscal 2027 Financial Results
Olympus Corporation (Olympus), a global MedTech company committed to advancing endoscopy-enabled care, today reported first quarter fiscal 2027 results for the three months ended June 30, 2026. First quarter revenue was 240.4 billion Japanese yen, up 16% year on year and up 5% in constant currency. Strong momentum in the Gastrointestinal Solutions (GIS) business drove growth. While the Surgical and Interventional Solutions (SIS) business was affected by voluntary ship holds, core franchises Urol
About this update from Olympus Corp.
Strong GIS Growth and Margin Expansion Support Full-Year Guidance TOKYO, Aug. 7, 2026 /PRNewswire/ -- Olympus Corporation (Olympus), a global MedTech company committed to advancing endoscopy-enabled care, today reported first quarter fiscal 2027 results for the three months ended June 30, 2026. First quarter revenue was 240.4 billion Japanese yen, up 16% year on year and up 5% in constant currency. Strong momentum in the Gastrointestinal Solutions (GIS) business drove growth. While the Surgical and Interventional Solutions (SIS) business was affected by voluntary ship holds, core franchises Urology and Respiratory delivered revenue growth. Olympus maintains the full-year FY2027 guidance provided in May 2026. First Quarter Key Highlights First Quarter Financial Results On a consolidated basis, revenue was ¥240.4 billion, up 16% year on year and up 5% in constant currency, with this increase also aided by a comparatively low prior-year base. Continued double-digit growth in GIS across Olympus' core markets, particularly in North America, Europe, and APAC, was the primary driver, with GIS revenue reaching ¥168.4 billion, up 21% year on year. North America delivered a strong quarter, reflecting continued customer demand supported by strong sales execution. This growth offset an approximately ¥13 billion temporary revenue headwind, primarily in SIS, related to ship holds and FDA-related import alerts. Excluding this temporary impact, the underlying business delivered a strong start to the year. SIS revenue was ¥71.9 billion, up 7% year on year. Despite the impact of voluntary ship holds and FDA-related import alerts, SIS continued to benefit from strong demand. This was driven by the strength of the product portfolio, particularly with the continued growth in the core franchises of Urology and Respiratory, which improved 14% and 15% year on year, respectively. On a constant currency basis, SIS revenue declined 4% due to the temporary impact of voluntary ship holds and FDA-related import alerts. The majority of ship-hold-affected products are expected to resume shipment in the second half of this fiscal year. Adjusted operating profit was ¥30.7 billion, up 133% year on year, with adjusted operating margin of 12.8%, an increase of 6.4 percentage points year on year (5.7 percentage points in constant currency). This improvement was driven by strong GIS...